Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Provention Bio Inc (PRVB)

Provention Bio Inc (PRVB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 437,288
  • Shares Outstanding, K 63,375
  • Annual Sales, $ 0 K
  • Annual Income, $ -98,580 K
  • 60-Month Beta 2.84
  • Price/Sales 624.76
  • Price/Cash Flow N/A
  • Price/Book 3.10
Trade PRVB with:

Options Overview Details

View History
  • Implied Volatility 91.17%
  • Historical Volatility 82.95%
  • IV Percentile 36%
  • IV Rank 14.32%
  • IV High 230.22% on 07/02/21
  • IV Low 67.93% on 01/08/21
  • Put/Call Vol Ratio 0.18
  • Today's Volume 208
  • Volume Avg (30-Day) 872
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 18,579
  • Open Int (30-Day) 16,754

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate -0.44
  • Number of Estimates 3
  • High Estimate -0.42
  • Low Estimate -0.45
  • Prior Year -0.58
  • Growth Rate Est. (year over year) +24.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.01 +15.64%
on 11/16/21
7.72 -9.97%
on 11/22/21
+0.41 (+6.27%)
since 11/01/21
3-Month
6.00 +15.83%
on 10/11/21
7.72 -9.97%
on 11/22/21
-0.04 (-0.57%)
since 09/01/21
52-Week
5.59 +24.33%
on 07/07/21
20.05 -65.34%
on 01/12/21
-8.93 (-56.23%)
since 12/01/20

Most Recent Stories

More News
Wall Street Analysts Predict a 167% Upside in Provention Bio, Inc. (PRVB): Here's What You Should Know

The consensus price target hints at a 167.3% upside potential for Provention Bio, Inc. (PRVB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings...

PRVB : 6.95 (+0.72%)
Provention Bio, Inc. (PRVB) Upgraded to Buy: What Does It Mean for the Stock?

Provention Bio, Inc. (PRVB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

PRVB : 6.95 (+0.72%)
How Much Upside is Left in Provention Bio, Inc. (PRVB)? Wall Street Analysts Think 187%

The average of price targets set by Wall Street analysts indicates a potential upside of 187.1% in Provention Bio, Inc. (PRVB). While the effectiveness of this highly sought-after metric is questionable,...

PRVB : 6.95 (+0.72%)
Provention Bio, Inc. (PRVB) Reports Q3 Loss, Misses Revenue Estimates

Provention Bio, Inc. (PRVB) delivered earnings and revenue surprises of 8.51% and -81.92%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?...

PRVB : 6.95 (+0.72%)
Provention Bio to Report Third Quarter 2021 Financial Results on November 4, 2021

/PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today...

PRVB : 6.95 (+0.72%)
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Provention Bio and Ontrak on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors of Provention Bio, Inc. (NASDAQ:...

PRVB : 6.95 (+0.72%)
OTRK : 5.85 (-3.62%)
Lifshitz Law Firm, P.C. Announces Investigations of ContextLogic, Inc. (NasdaqGS: WISH), Provention Bio, Inc. (NasdaqGS: PRVB), Ubiquiti Inc. (NYSE: UI), and Virgin Galactic holdings, Inc. (NYSE: SPCE)

NEW YORK, Aug. 06, 2021 (GLOBE NEWSWIRE) -- ContextLogic, Inc. (NasdaqGS: WISH)

WISH : 3.35 (-10.19%)
PRVB : 6.95 (+0.72%)
UI : 296.67 (-0.88%)
SPCE : 14.86 (-7.13%)
Last Few Hours to Actively Participate in Provention Bio, Inc. (PRVB) Class Action - Bronstein, Gewirtz & Grossman, LLC

NEW YORK, July 19, 2021 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Provention Bio, Inc. ("Provention"...

PRVB : 6.95 (+0.72%)
DEADLINE ALERT for UI, PRVB, and WPG: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

LOS ANGELES, July 19, 2021 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded...

UI : 296.67 (-0.88%)
PRVB : 6.95 (+0.72%)
WPG : 0.8323 (-1.00%)
PRVB Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Provention Bio, Inc. Investors of Class Action and Lead Plaintiff Deadline: July 20, 2021

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB) and certain...

PRVB : 6.95 (+0.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Provention Bio, Inc. is a biopharmaceutical company. It focuses on development of novel therapeutics and solutions to intercept and prevent immune-mediated disease. The company's product pipeline consists of PRV-031, PRV-6527, PRV-300, PRV-3279 and PRV-101 which are in clinical stage. Provention Bio,...

See More

Key Turning Points

3rd Resistance Point 7.44
2nd Resistance Point 7.32
1st Resistance Point 7.13
Last Price 6.95
1st Support Level 6.82
2nd Support Level 6.70
3rd Support Level 6.51

See More

52-Week High 20.05
Fibonacci 61.8% 14.53
Fibonacci 50% 12.82
Fibonacci 38.2% 11.11
Last Price 6.95
52-Week Low 5.59

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar